Verastem Oncology
- Biotech or pharma, therapeutic R&D
Verastem Oncology is focused development stage company with a promising pipeline of targeted cancer agents, comprised of defactinib, a FAK inhibitor, and VS-6766, a novel RAF/MEK inhibitor
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}